Towards Healthcare
Radionuclide Drug Conjugates (RDC) Market Expands USD 8.87 Billion by 2034

Radionuclide Drug Conjugates (RDC) Market Trends 2025 PSMA & AI Integration Reshape Oncology

Market insights predict the global radionuclide drug conjugates (RDC) industry will increase from USD 3.24 billion in 2024 to USD 8.87 billion by 2034, achieving a CAGR of 10.54%. The global radionuclide drug conjugates (RDC) market is growing strongly due to the growing cases of genetic disorders. North America is dominating due to technological advancements and investment in the pharma and biotech sectors.

  • Insight Code: 5949
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The radionuclide drug conjugates (RDC) market is projected to reach USD 8.87 billion by 2034, growing at a CAGR of 10.54% from 2024 to 2034.

North America is currently leading the radionuclide drug conjugates (RDC) market due to rising advancements in healthcare practices, especially in precision medicine.

Some key players include Novartis AG, Bayer AG, Fusion Pharmaceuticals, Telix Pharmaceuticals, Lantheus Holdings, Inc., Curium Pharma, etc. 

Key trends include rising demand for precision medicine and growing cases of cancer.

There are already 15 FDA-approved antibody-drug conjugates that target 16 distinct cancer indications as of December 2024.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.